Last Updated on December 27, 2024 by The Health Master
Misleading Drug Advertisements
In a concerted effort to combat the proliferation of misleading drug advertisements, the Drugs Control Administration Telangana (DCA Telangana) has seized seven different medicines within the last two days.
These seizures, which bring the total number of such actions this year to over 60, underscore the ongoing battle against deceptive marketing practices in the pharmaceutical industry.
PMO Directs Strict Action:
The Prime Minister’s Office (PMO) has issued a strong directive to the Ministry of Health, demanding a firm crackdown on misleading drug advertisements.
This directive specifically emphasizes the need to amend the existing Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
The proposed amendments aim to significantly expand the scope of the Act to encompass a wider range of deceptive claims, including those related to Ayush medicines.
Years of Stalled Progress:
Despite being proposed on February 3, 2020, the crucial amendment to the 1954 Act has remained stagnant for four years.
This delay raises concerns about the effectiveness of regulatory measures in curbing deceptive marketing practices in the healthcare sector.
Scope of the Act:
The Act, which encompasses all categories of medicines, including Ayurvedic, Siddha, Unani, and Homeopathy, currently prohibits advertisements that make exaggerated or unsubstantiated claims of magical cures or treatments.
The proposed amendments seek to broaden the Act’s reach by incorporating 24 additional categories of diseases and disorders into its purview.
These include sensitive areas such as skin whitening, height enhancement, premature aging, and sexual performance enhancement.
Recent Seizures:
Among the recent seizures by the DCA Telangana:
- Neem Churnam: This Ayurvedic medicine, manufactured by Arogya Rama Herbals, was found to be marketed with the misleading drug advertisements claiming treating fever. This blatant disregard for the 1954 Act led to its seizure.
- Febral Fever Elixir: A homeopathic medicine, this product was also found to make unsubstantiated claims of treating fever.
- Fever Go Syrup: Another Ayurvedic medicine, this syrup was similarly seized for making false claims about its ability to treat fever.
- App-up Plus Syrup: This allopathic medicine was found to make deceptive claims regarding growth and weight promotion.
Key Takeaways:
- The DCA Telangana has intensified its efforts to curb misleading drug advertisements.
- The PMO has directed the Ministry of Health to take strict action against such practices.
- The proposed amendments to the 1954 Act are crucial for effectively combating deceptive marketing in the healthcare sector.
- Consumers should be vigilant and exercise caution when evaluating claims made in drug advertisements.
-
What is the purpose of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954?
This Act aims to prevent the dissemination of misleading and deceptive advertisements related to all categories of medicines, including Ayurvedic, Siddha, Unani, and Homeopathy.
-
What are the proposed amendments to the 1954 Act?
The proposed amendments aim to expand the Act’s scope to include 24 additional categories of diseases and disorders, such as skin whitening, height enhancement, and sexual performance enhancement.
-
Why is the amendment to the 1954 Act important?
The amendment is crucial for strengthening consumer protection and ensuring that consumers are not misled by deceptive marketing claims related to healthcare products.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Note: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns.
Constitutionality of the provisions of DMROA- Articl
Supreme Court stays notification omitting Misleading Advertisement Rule
Court imposes Rs. 90,000 fine on 4 Pharma Units for misleading Ads
Key Notes on Revised Schedule M: Point No. 14 – Materials
USFDA issues VAI status to Biocon for Bengaluru API facility
Bulk drug import from China continues to rise in 5 years
Stay action against Pharma units manufacturing Nutraceuticals: High Court
NPPA fixed retail price of 7 formulations: December 2024
Revised Schedule M: Industry seeks balance between Quality and Viability
FDA Karnataka enters a New Era of Food and Drug Safety
Key Notes on Revised Schedule M: Point No. 13 – Equipment
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
